A Phase 3 interventional study of Oncoxin and Placebo in Breast Fibrocystic Disease, sponsored by Catalysis SL. Completed at 1 site in Cuba. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-05-04.
Sponsored by Catalysis SL · Phase 3, Interventional, and Treatment
The purpose of the study is to evaluate whether Oncoxin, a nutritional supplement, improves the clinical and ultrasonographic results in comparison with placebo during 24 weeks of treatment.
11 studies on the registry are indexed under Fibrocystic Breast Disease; 1 is open to participants now.
Browse Fibrocystic Breast Disease studies →Catalysis SL is the lead sponsor of 53 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oncoxin, a nutritional supplement
Dietary Supplement: Oncoxin
Dietary Supplement: Placebo
(caplets 300 mg), three oral caplets per day for 24 weeks
(caplets 300 mg), three oral caplets per day for 24 weeks
The ultrasonographic improvement at 24 weeks (end of the treatment)
Time frame: 24 weeks
Adverse effects at 24 weeks (end of the treatment)
Time frame: 24 weeks
Lesion size according clinical measurement at 24 weeks (end of the treatment)
Time frame: 24 weeks
Pain according patient examination at 24 weeks (end of the treatment)
Time frame: 24 weeks
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Green Tea Extract-based Antioxidant Supplement